- Our Services
-
Patients and Families
- Get Directions
- Parking
- Childrens Locations
- Getting Around
- Guidelines for Visitors
- Contact a Patient
- Contact Children's
- Send an e-Card
- Gift Shop
Planning a Visit
- Find a Doctor
- Make an Appointment
- Child Health A-Z
- Community Ed.Classes
- Injury Prevention
- International Patients
- Medical Records
- Patient Handbook
- Patient Procedures
Parents
- For Health Professionals
- Research
- Ways to Give
- News
Research
Vesicoureteral Reflux (VUR) NIH Clinical Trial
Purpose
|
The purpose of this study is to learn whether all children with vesicoureteral reflux (VUR) should be treated with antibiotics. The study will tell us if prophylactic antibiotic treatment prevents urinary tract infections (UTIs) and renal scarring in children with VUR.
Study Description
VUR is a condition in which urine goes up from the bladder into the ureters during urination. VUR is found in 30 — 40 percent of children who had a UTI, and is thought to increase the risk of kidney damage when children have recurrent UTIs. Currently, children are treated with a small daily dose of antibiotics (often for several years) in hope of preventing recurrent UTIs and kidney damage. This practice has been based on information provided by a study during the 1980s in children with severe VUR who received prophylactic antibiotics or surgery; an observation group was not included in that study. There have been no well-designed research studies to show that this practice is necessary in all children with VUR.
The RIVUR Study (Randomized Intervention for Children with Vesicoureteral Reflux) is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. It will be conducted in 19 specialty clinics across the United States.
Children participating in the RIVUR Study will be randomly assigned to one of two treatment groups. One group will receive the antibiotics. The other group will receive a placebo, a liquid that looks and tastes exactly like the active medication, but contains no medicine. All children in the RIVUR study will continue in the study for 2 years, and be closely monitored for UTIs and kidney health. The study team will provide participant families with educational materials, and will stay in close contact through phone calls and study visits.
The RIVUR Study has the potential to help us understand how to provide the best care for the tens of thousands of children who are diagnosed each year with VUR and UTI.
Status: Enrollment Closed
Additional Resources
- VUR Additional Resources
- Study Personnel Directory (PDF)
- Web cast: Urinary Tract Infection and Vesicoureteral Reflux: Are We Doing Enough or Too Much?
- Webcast Excerpt Related to NIH VUR Clinical Trial
- RIVUR National Website
- List of Institutions Participating in the National Study
- RIVUR study on ClinicalTrials.gov
Eligibility Criteria
- At least 2 months of age, but less than 6 years old
- First or second UTI with fever or symptoms within 16 weeks
- Effective treatment for the first UTI for at least 7 days
- VUR grade I-IV
- No history of other renal injury or serious disease
- No allergies to sulfa medications
- Meet a few additional eligibility requirements
Contact Information
For more information, contact Alejandro Hoberman, MD, Chief, Division of General Academic Pediatrics, at 412-999-3277.
Toolkit for PhysiciansHow to refer your next patient with UTI/VUR:
|
Last Update
March 1, 2012
March 1, 2012

Expert in Pediatric Rehabilitation Medicine Appointed Chief
Study of Peptide Vaccines in Children with Gliomas
Study Finds Effective Tool in Preventing Teen Dating Violence